Anti-Cluster of Differentiation 59 (CD59) Monoclonal Antibody Homo sapiens (Human) Protein, Antibody, Assaykit, Service

Protectin; MIC11; MIN1; MIN2; MIN3; MSK21; MAC-IP; MACIF; MIRL; HRF20; Complement Regulatory Protein; 20 kDa homologous restriction factor; Membrane attack complex inhibition factor

Add to Cart Distributors
Overview
Properties
  • Ig Isotype IgG1 Kappa, Clone Number D1
  • PurificationProtein A + Protein G affinity chromatography
  • LabelNone
  • Excitation Laser
  • Vol. per test
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Anti-Cluster of Differentiation 59 (CD59) Monoclonal Antibody Packages (Simulation)
  • Anti-Cluster of Differentiation 59 (CD59) Monoclonal Antibody Packages (Simulation)
  • Anti-Cluster of Differentiation 59 (CD59) Monoclonal Antibody Human peripheral blood lymphocytes were stained with 20µg/ml mouse Anti-human CD59 Monoclonal Antibodies (Catalog # FAB336Hu02, left) or Isotype control antibody (Catalog # IS067-Mu01, right), followed by 1µg/ml FITC-conjugated Anti-mouse IgG Secondary Antibody (Catalog # SAA544Mu18).
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Usage

For flow cytometry, the suggested use of this reagent is 0.5-1 µg per 10^6 cells in 100 µl volume.
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Giveaways

Citations

  • Soluble CD59 is a Novel Biomarker for the Prediction of Obstructive Chronic Lung Allograft Dysfunction After Lung TransplantationPubmed:27215188
  • Salivary levels of last generation specific pro©\resolving lipid mediators (SPMs)(protectin and maresin) in patients with cardiovascular and periodontal disease: A case ¡­33650687

Recommend products